预约演示
AbbVie cuts ties to Harpoon’s BCMA trispecific, puncturing dream of $200M payday
临床1期临床3期引进/卖出
Harpoon had expected to deliver phase 1 data to AbbVie by the end of the year.
AbbVie secured an optHarpoon Therapeuticsldwide license for HPN217 late in 2019, when it paid Harpoon $30 million upfront and dangled many times that amHPN217n AbbVieial future paydays. Harpoon netted another $50 million when it dosed the first patient in a phase 1/2 clinical trial in 2020 and went on to link a high dose of the candidate to a 77% response rate in a small cohort of multiple myeloma patients.
AbbVieonth, Harpoon told investors it expected to deliver thHPN217e 1 dataset to AbbVie by theHarpoon the year. Now, AbbVie has walked away from the program, dropping its option on a canHarpoonthat binds to BCMA on cancer cells, CD3 on T cells and albumin for half-life extension.multiple myeloma
The decisionHarpoonAbbVie from the need to pay $200 million and commit to $230 miAbbVie for an asset in one of the moAbbViegested areas of oncology. A who’s who of drug developers is going after BCMA with maBCMAf thcancerlities iCD3heir arsenals. Aalbumin several treatments already on the market, programs at the back of the pack face a battle to find a point of difference that can translate into commercial success.
One option is to poAbbVie candidates as treatments for patients who relapse after receiving other BCMA therapies. If BCMA therapies are useoncology but eventually fail most patients, the class will create a new unmet need. AstraZeneca, Bristol Myers Squibb, Johnson & Johnson and Roche have identified GPRC5D as a way to treat post-BCMA patients. Harpoon is positioning HPN217 as a challenger for the market.
“There is a significant unmet medical need for patients living with advanced multiple myeloma who have progressed after prior treatments, including patients with prior BCMA-targeted therapies, and we remain confident in HPNAstraZenecatiBristol Myers SquibbtiJohnson & Johnsonated Rochement option,” HarGPRC5DEO Julie Eastland said in a statement.HarpoonHPN217
When Harpoon shared phase 1 data late last year, 22% of the participadvanced multiple myelomaved BCMA therapy. The biotech is scheduled to share more data from the studBCMAter this month. Ahead of the data drop, EastlandHPN217investors the preliminary results “continue to be encouraging with a favoHarpoonafety profile.”
HarpoHarpoonar from alone in continuing to see opportunities for BCMA T-cell engagers. Pfizer hasBCMAen a candidate into phase 3, Regeneron is on the cusp of starting its own phase 3 and BMS has a prospect in phaEastlandbVie, having exercised its option on TeneoOne in 2021, has its own BCMAxCD3 bispecific in early-phase development.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。